Managing GLP-1–Related Nausea: Practical Considerations for Healthcare Providers


Managing Common GLP1 Symptoms

GLP-1 receptor agonists are increasingly used in the management of type 2 diabetes and obesity. As utilization continues to grow, healthcare providers are focused not only on clinical outcomes but also on helping patients navigate potential treatment experiences.

Gastrointestinal effects, including nausea, are among the most reported adverse events associated with GLP-1 therapy.¹,²

Understanding Why Nausea May Occur

GLP-1 receptor agonists influence multiple pathways involved in metabolic regulation, including appetite control, satiety signaling, and gastrointestinal function.³

These mechanisms contribute to therapeutic effects but may also contribute to gastrointestinal experiences reported by some patients.

Supporting Patient Conversations

Patient education may help individuals better understand what they may experience during treatment. Healthcare providers may consider discussing:

  • Potential gastrointestinal effects associated with therapy 
  • Individual variability in patient experience 
  • The importance of communicating persistent or bothersome symptoms 
  • Supportive strategies that may be appropriate for individual patients 

Advanced Herbals Ginger Chews Clinical Resource

Prestige Consumer Healthcare conducted a double-blind, placebo-controlled pilot study evaluating ginger chews among individuals experiencing GLP-1–associated nausea.4

The findings provide additional insight into the potential role of ginger as a supportive option for individuals experiencing nausea associated with GLP-1 therapy.

REFERENCES

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. Available from: 
https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

2. Pi-Sunyer X, Astrup A, Fjioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22. Available from: 
https://www.nejm.org/doi/full/10.1056/NEJMoa1411892

3. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. Available from: 
https://pmc.ncbi.nlm.nih.gov/articles/PMC5573908/

4. Balaban DH, McNamara S, Wallman K, et al. Investigation of ginger chews to decrease glucagon-like peptide-1 (GLP-1) nausea. Clinical study FY25_DRA.36; Prestige Consumer Healthcare, data on file.

Review and commentary publications available from: 

Tucker ME. Ginger Dietary Supplement May Ease GLP-1-Related Nausea. Medscape. Published 14April2026. Assessed 13Oct2026. https://www.medscape.com/viewarticle/ginger-dietary-supplement-may-ease-glp-1-related-nausea-2026a1000bk9?form=fpf

Friis C. Highlights from SGNA 2026. Investigation of ginger vs. placebo to decrease nausea associated with glucagon-like peptide-1 therapy (Balaban et al). Gastroenterology & Endoscopy News. Published 21Sep2026. Assessed 13Oct2026. https://www.gastroendonews.com/Endoscopy-Reprocessing-Infection-Prevention-and-Operations/Article/09-26/SGNA-2026-Research-Highlights/81622

Dramamine Products

Where to buy Dramamine